Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:11 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
JHS Svendgaard Laboratories Ltd operates within the personal care industry and has seen fluctuating revenue trends over recent years. For the fiscal year ending March 2025, the company reported sales of ₹92.00 Cr, a decline from the ₹84.81 Cr recorded in March 2023. The trailing twelve months (TTM) sales stood at ₹93.56 Cr, indicating a slight recovery compared to the previous fiscal year. Quarterly sales figures also reflect volatility, with the highest quarterly sales of ₹25.17 Cr recorded in March 2025, while the lowest was ₹14.30 Cr in December 2023. This inconsistency in revenue generation raises concerns regarding the company’s market positioning and demand stability. The overall sales trajectory shows a decline over the past few years, particularly from a peak of ₹140.29 Cr in March 2018, highlighting the need for strategic initiatives to bolster revenue growth moving forward.
Profitability and Efficiency Metrics
Profitability at JHS Svendgaard Laboratories remains a significant challenge, as evidenced by its negative net profit of ₹19.74 Cr for the fiscal year 2025, compared to a loss of ₹17.52 Cr in 2023. The operating profit margin (OPM) stood at -4.36% for March 2025, indicating ongoing operational inefficiencies. The company has struggled with consistent losses over recent fiscal periods, with a negative operating profit recorded in several quarters, including a low of -21.37% in March 2025. Efficiency metrics such as the cash conversion cycle (CCC) stood at 63 days, which is relatively manageable but reflects longer working capital cycles compared to industry norms. The interest coverage ratio (ICR) was reported at -2.01x, suggesting that the company is not generating enough operating profit to cover its interest obligations, which raises significant concerns for long-term sustainability and financial health.
Balance Sheet Strength and Financial Ratios
As of March 2025, JHS Svendgaard Laboratories reported total borrowings of ₹10.59 Cr against reserves of ₹88.04 Cr, providing a reasonable buffer for financial stability. The current ratio of 2.18 indicates a strong liquidity position, suggesting that the company can cover its short-term liabilities comfortably. However, the return on equity (ROE) was reported at a low 10.8%, while the return on capital employed (ROCE) stood at 5.19%, both of which are below typical industry benchmarks. The price-to-book value (P/BV) ratio at 0.55x indicates that the stock is trading below its book value, which may suggest undervaluation or market skepticism regarding future growth. The company’s total debt to equity ratio of 0.02 indicates a low level of leverage, reflecting prudent financial management, but the persistent losses necessitate a review of operational strategies to enhance profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of JHS Svendgaard reveals a significant public shareholding of 63.87%, indicating a broad base of retail investors. Promoter holdings have decreased to 34.56%, down from 42.23% in December 2022, which may signal reduced confidence from the promoters or a shift in strategy. Foreign institutional investors (FIIs) hold 1.57%, while domestic institutional investors (DIIs) have no reported stake, reflecting limited institutional interest in the company. The total number of shareholders has decreased from 24,308 in December 2022 to 25,007 by September 2025, indicating a slight recovery in shareholder retention. The declining promoter stake, coupled with stagnant institutional interest, raises concerns regarding the company’s ability to attract long-term investment and build investor confidence in its growth prospects.
Outlook, Risks, and Final Insight
Looking forward, JHS Svendgaard Laboratories faces several risks, including ongoing profitability challenges and market volatility. The decline in revenue and net profit margins presents a significant risk to its operational sustainability. However, strengths such as a strong liquidity position and low leverage provide a foundation for potential recovery. The company must focus on enhancing operational efficiencies and exploring new market opportunities to reverse its declining sales trend. Strategic initiatives aimed at improving product offerings and expanding distribution channels could be beneficial. The outlook hinges on the management’s ability to navigate these challenges effectively while leveraging its current strengths to regain market share and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,844 Cr. | 272 | 334/190 | 71.1 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 41.2 Cr. | 24.0 | 37.0/22.3 | 80.8 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 120 Cr. | 125 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 561 Cr. | 369 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 9,153 Cr. | 249 | 423/244 | 25.0 | 55.8 | 1.40 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,264.71 Cr | 1,856.86 | 57.37 | 112.70 | 0.79% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 |
| Expenses | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 |
| Operating Profit | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 |
| OPM % | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% | 4.08% |
| Other Income | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 | 1.14 |
| Interest | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.20 |
| Depreciation | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 |
| Profit before tax | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 |
| Tax % | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% | 1,800.00% |
| Net Profit | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.20 |
| EPS in Rs | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 |
Last Updated: December 30, 2025, 9:16 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 22.28 Cr.. The value appears to be declining and may need further review. It has decreased from 23.45 Cr. (Jun 2025) to 22.28 Cr., marking a decrease of 1.17 Cr..
- For Expenses, as of Sep 2025, the value is 21.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 21.79 Cr. (Jun 2025) to 21.37 Cr., marking a decrease of 0.42 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.91 Cr.. The value appears to be declining and may need further review. It has decreased from 1.66 Cr. (Jun 2025) to 0.91 Cr., marking a decrease of 0.75 Cr..
- For OPM %, as of Sep 2025, the value is 4.08%. The value appears to be declining and may need further review. It has decreased from 7.08% (Jun 2025) to 4.08%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 1.14 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 1.14 Cr., marking an increase of 0.14 Cr..
- For Interest, as of Sep 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.16 Cr. (Jun 2025) to 0.20 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 1.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.88 Cr. (Jun 2025) to 1.86 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Jun 2025) to -0.01 Cr., marking a decrease of 0.63 Cr..
- For Tax %, as of Sep 2025, the value is 1,800.00%. The value appears to be increasing, which may not be favorable. It has increased from -69.35% (Jun 2025) to 1,800.00%, marking an increase of 1,869.35%.
- For Net Profit, as of Sep 2025, the value is -0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Jun 2025) to -0.20 Cr., marking a decrease of 1.26 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.02. The value appears to be declining and may need further review. It has decreased from 0.12 (Jun 2025) to -0.02, marking a decrease of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.28 | 55.10 | 99.62 | 104.18 | 140.29 | 123.99 | 139.11 | 100.77 | 86.25 | 84.81 | 70.80 | 92.00 | 93.56 |
| Expenses | 39.06 | 58.95 | 93.11 | 92.45 | 126.34 | 123.89 | 137.40 | 98.80 | 87.09 | 93.88 | 71.73 | 96.01 | 96.12 |
| Operating Profit | -3.78 | -3.85 | 6.51 | 11.73 | 13.95 | 0.10 | 1.71 | 1.97 | -0.84 | -9.07 | -0.93 | -4.01 | -2.56 |
| OPM % | -10.71% | -6.99% | 6.53% | 11.26% | 9.94% | 0.08% | 1.23% | 1.95% | -0.97% | -10.69% | -1.31% | -4.36% | -2.74% |
| Other Income | -2.67 | -5.79 | -17.30 | 0.39 | 32.03 | 5.97 | 3.16 | 7.49 | 9.39 | -7.31 | 4.31 | 0.02 | 0.97 |
| Interest | 14.14 | 0.14 | 0.36 | 0.62 | 0.74 | 1.03 | 1.95 | 1.24 | 1.39 | 0.55 | 0.46 | 0.57 | 0.70 |
| Depreciation | 14.71 | 12.36 | 10.49 | 6.36 | 6.81 | 7.09 | 8.76 | 7.25 | 7.05 | 6.02 | 6.35 | 7.95 | 7.73 |
| Profit before tax | -35.30 | -22.14 | -21.64 | 5.14 | 38.43 | -2.05 | -5.84 | 0.97 | 0.11 | -22.95 | -3.43 | -12.51 | -10.02 |
| Tax % | -18.39% | 0.18% | 0.00% | -326.85% | 32.19% | -18.54% | -16.95% | -39.18% | 4,000.00% | -23.66% | 18.37% | 57.87% | |
| Net Profit | -28.81 | -22.18 | -21.64 | 21.94 | 26.06 | -1.67 | -4.86 | 1.34 | -4.29 | -17.52 | -4.06 | -19.74 | -7.94 |
| EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.92 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 23.01% | 2.43% | 201.39% | 18.78% | -106.41% | -191.02% | 127.57% | -420.15% | -308.39% | 76.83% | -386.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | -20.58% | 198.95% | -182.61% | -125.19% | -84.61% | 318.59% | -547.72% | 111.76% | 385.22% | -463.03% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -8% |
| 3 Years: | 2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -624% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -9% |
| 3 Years: | -23% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: December 10, 2025, 2:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.10 | 24.10 | 37.64 | 44.12 | 60.90 | 60.90 | 60.90 | 64.40 | 64.90 | 78.40 | 78.40 | 85.60 | 85.60 |
| Reserves | 38.01 | 95.50 | 62.95 | 90.25 | 113.36 | 115.94 | 117.10 | 124.30 | 121.00 | 95.44 | 91.49 | 87.12 | 88.04 |
| Borrowings | 54.12 | 18.82 | 2.56 | 2.31 | 2.49 | 7.19 | 8.58 | 7.01 | 6.19 | 2.58 | 5.13 | 6.46 | 10.59 |
| Other Liabilities | 74.19 | 32.93 | 19.26 | 18.57 | 31.59 | 38.54 | 54.88 | 32.72 | 30.01 | 51.81 | 22.04 | 24.62 | 22.67 |
| Total Liabilities | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
| Fixed Assets | 120.88 | 107.89 | 65.10 | 65.00 | 71.41 | 70.81 | 65.63 | 63.22 | 58.52 | 65.07 | 90.41 | 90.33 | 88.32 |
| CWIP | 0.03 | 0.03 | 0.68 | 0.67 | 0.51 | 4.80 | 7.05 | 8.92 | 19.96 | 8.57 | 0.82 | 0.00 | 2.95 |
| Investments | 0.00 | 0.00 | 0.00 | 1.03 | 18.19 | 9.75 | 6.03 | 2.05 | 3.62 | 2.97 | 3.45 | 3.64 | 4.88 |
| Other Assets | 69.51 | 63.43 | 56.63 | 88.55 | 118.23 | 137.21 | 162.75 | 154.24 | 140.00 | 151.62 | 102.38 | 109.83 | 110.75 |
| Total Assets | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 85.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 85.60 Cr..
- For Reserves, as of Sep 2025, the value is 88.04 Cr.. The value appears strong and on an upward trend. It has increased from 87.12 Cr. (Mar 2025) to 88.04 Cr., marking an increase of 0.92 Cr..
- For Borrowings, as of Sep 2025, the value is 10.59 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.46 Cr. (Mar 2025) to 10.59 Cr., marking an increase of 4.13 Cr..
- For Other Liabilities, as of Sep 2025, the value is 22.67 Cr.. The value appears to be improving (decreasing). It has decreased from 24.62 Cr. (Mar 2025) to 22.67 Cr., marking a decrease of 1.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 206.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
- For Fixed Assets, as of Sep 2025, the value is 88.32 Cr.. The value appears to be declining and may need further review. It has decreased from 90.33 Cr. (Mar 2025) to 88.32 Cr., marking a decrease of 2.01 Cr..
- For CWIP, as of Sep 2025, the value is 2.95 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.95 Cr., marking an increase of 2.95 Cr..
- For Investments, as of Sep 2025, the value is 4.88 Cr.. The value appears strong and on an upward trend. It has increased from 3.64 Cr. (Mar 2025) to 4.88 Cr., marking an increase of 1.24 Cr..
- For Other Assets, as of Sep 2025, the value is 110.75 Cr.. The value appears strong and on an upward trend. It has increased from 109.83 Cr. (Mar 2025) to 110.75 Cr., marking an increase of 0.92 Cr..
- For Total Assets, as of Sep 2025, the value is 206.90 Cr.. The value appears strong and on an upward trend. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
Notably, the Reserves (88.04 Cr.) exceed the Borrowings (10.59 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.90 | -22.67 | 3.95 | 9.42 | 11.46 | -7.09 | -6.87 | -5.04 | -7.03 | -11.65 | -6.06 | -10.47 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
| Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
| Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
| Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
| Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
| ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Diluted EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Cash EPS (Rs.) | -1.38 | 0.29 | -1.43 | 0.42 | 1.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Revenue From Operations / Share (Rs.) | 10.75 | 9.03 | 14.82 | 13.29 | 15.65 |
| PBDIT / Share (Rs.) | -0.13 | 0.43 | 0.81 | 1.32 | 1.47 |
| PBIT / Share (Rs.) | -1.06 | -0.37 | -0.33 | 0.23 | 0.34 |
| PBT / Share (Rs.) | -1.46 | -0.43 | -3.37 | 0.01 | 0.15 |
| Net Profit / Share (Rs.) | -2.31 | -0.51 | -2.58 | -0.66 | 0.20 |
| NP After MI And SOA / Share (Rs.) | -2.31 | -0.51 | -2.38 | -0.62 | 0.18 |
| PBDIT Margin (%) | -1.23 | 4.77 | 5.50 | 9.91 | 9.39 |
| PBIT Margin (%) | -9.87 | -4.19 | -2.25 | 1.73 | 2.19 |
| PBT Margin (%) | -13.59 | -4.84 | -22.70 | 0.11 | 0.96 |
| Net Profit Margin (%) | -21.46 | -5.73 | -17.43 | -4.97 | 1.33 |
| NP After MI And SOA Margin (%) | -21.46 | -5.73 | -16.07 | -4.69 | 1.18 |
| Return on Networth / Equity (%) | -11.43 | -2.38 | -8.96 | -2.17 | 0.63 |
| Return on Capital Employeed (%) | -5.14 | -1.70 | -1.09 | 0.73 | 1.07 |
| Return On Assets (%) | -9.81 | -2.05 | -6.54 | -1.82 | 0.52 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.46 | 0.32 | 0.41 | 0.36 | 0.42 |
| Current Ratio (X) | 2.18 | 1.87 | 2.36 | 4.18 | 5.23 |
| Quick Ratio (X) | 1.70 | 1.33 | 2.00 | 3.54 | 4.73 |
| Inventory Turnover Ratio (X) | 7.50 | 3.11 | 4.36 | 5.16 | 8.94 |
| Interest Coverage Ratio (X) | -2.01 | 7.34 | 5.09 | 6.13 | 7.63 |
| Interest Coverage Ratio (Post Tax) (X) | -28.88 | -7.82 | 2.78 | -2.08 | 2.08 |
| Enterprise Value (Cr.) | 81.22 | 121.69 | 70.51 | 136.74 | 117.07 |
| EV / Net Operating Revenue (X) | 0.88 | 1.72 | 0.73 | 1.59 | 1.16 |
| EV / EBITDA (X) | -71.68 | 36.03 | 13.31 | 15.99 | 12.37 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| Price / BV (X) | 0.55 | 0.75 | 0.59 | 0.71 | 0.68 |
| Price / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| EarningsYield | -0.20 | -0.03 | -0.15 | -0.03 | 0.01 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.38. This value is below the healthy minimum of 3. It has decreased from 0.29 (Mar 24) to -1.38, marking a decrease of 1.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.75. It has increased from 9.03 (Mar 24) to 10.75, marking an increase of 1.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to -0.13, marking a decrease of 0.56.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.06. This value is below the healthy minimum of 0. It has decreased from -0.37 (Mar 24) to -1.06, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.46. This value is below the healthy minimum of 0. It has decreased from -0.43 (Mar 24) to -1.46, marking a decrease of 1.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For PBDIT Margin (%), as of Mar 25, the value is -1.23. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 24) to -1.23, marking a decrease of 6.00.
- For PBIT Margin (%), as of Mar 25, the value is -9.87. This value is below the healthy minimum of 10. It has decreased from -4.19 (Mar 24) to -9.87, marking a decrease of 5.68.
- For PBT Margin (%), as of Mar 25, the value is -13.59. This value is below the healthy minimum of 10. It has decreased from -4.84 (Mar 24) to -13.59, marking a decrease of 8.75.
- For Net Profit Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 5. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 8. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.43. This value is below the healthy minimum of 15. It has decreased from -2.38 (Mar 24) to -11.43, marking a decrease of 9.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.14. This value is below the healthy minimum of 10. It has decreased from -1.70 (Mar 24) to -5.14, marking a decrease of 3.44.
- For Return On Assets (%), as of Mar 25, the value is -9.81. This value is below the healthy minimum of 5. It has decreased from -2.05 (Mar 24) to -9.81, marking a decrease of 7.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has increased from 0.32 (Mar 24) to 0.46, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 2.18, marking an increase of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.70, marking an increase of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.50. This value is within the healthy range. It has increased from 3.11 (Mar 24) to 7.50, marking an increase of 4.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.01. This value is below the healthy minimum of 3. It has decreased from 7.34 (Mar 24) to -2.01, marking a decrease of 9.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -28.88. This value is below the healthy minimum of 3. It has decreased from -7.82 (Mar 24) to -28.88, marking a decrease of 21.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 81.22. It has decreased from 121.69 (Mar 24) to 81.22, marking a decrease of 40.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 1.72 (Mar 24) to 0.88, marking a decrease of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is -71.68. This value is below the healthy minimum of 5. It has decreased from 36.03 (Mar 24) to -71.68, marking a decrease of 107.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For Price / BV (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.55, marking a decrease of 0.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.20, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -21.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.14% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.43% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -28.88
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 57.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -21.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
| Mr. Nikhil Nanda | Managing & Executive Director |
| Mr. Vinay Mittal | Non Executive Director |
| Mr. Kapil Minocha | Independent Director |
| Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 24 January 2026) is ₹25.46 which is 135.74% higher the current market price of ₹10.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹92.9 Cr. market cap, FY2025-2026 high/low of ₹20.7/8.66, reserves of ₹88.04 Cr, and liabilities of ₹206.90 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 92.9 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 24 January 2026?
The current stock price of JHS Svendgaard Laboratories Ltd as on 24 January 2026 is ₹10.8.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is ₹20.7/8.66.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.3.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.